R&D In Brief: Sucampo/Takeda, Amgen, Merck/Endocyte
Executive Summary
Sucampo/Takeda stumble with new formulation of Amitiza; Amgen makes progress with melanoma vaccine T-Vec and PCSK9 inhibitor evolocumab; Merck/Endocyte see positive signs for vintafolide in lung cancer, positive opinion in ovarian.
You may also be interested in...
Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.